Latest Telehealth News

BCAL Diagnostics has embedded referral forms for its early cancer detection tests into clinical software used by 97% of Australian GPs, launched a telehealth platform, and opened a Sydney clinic, gearing up for a multi-cancer test launch in June 2026.

Doctor Care Anywhere has snapped up the GLP-1 and medicated weight-loss business of Outcome Diagnostics and MedicSpot for £850,000, adding £5.3 million in trailing revenue and expanding its direct-to-consumer footprint in the UK.

EMVision is broadening its emu™ Pivotal Trial to include acute ischaemia detection, aiming to accelerate FDA clearance and enhance the brain scanner's clinical impact. Recruitment has passed 125 patients across US and Australian sites, with full enrolment expected by early 2027.

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

Doctor Care Anywhere posted an 8.4% quarterly jump in consultations and sustained positive cashflow for the fourth consecutive quarter, while launching new digital health initiatives and reaffirming its medium-term revenue and profitability targets.

Vitura Health’s telehealth arm, Doctors on Demand, has hit a major milestone of over 1 million consultations since FY2024, while delivering sustained EBITDA profitability and a 54% revenue increase over two years to $21.6 million in FY2026 Q1-Q3.

Vitura Health has appointed Justin James as its new CEO, bringing a wealth of healthcare leadership and a proven track record in specialty therapies to accelerate the company’s transformation.

Eve Health Group is advancing its proprietary reformulation platform with two fast-onset products launched under Australia's SAS-B pathway, targeting large underserved markets in women's and men's health. The company’s capital-light, partner-led model aims for rapid revenue growth post-ARTG registration.

Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.

Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.